Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Elucidating the Lipid Binding Properties of Membrane-Active Peptides Using Cyclised Nanodiscs.

Zhang AH, Edwards IA, Mishra BP, Sharma G, Healy MD, Elliott AG, Blaskovich MAT, Cooper MA, Collins BM, Jia X, Mobli M.

Front Chem. 2019 Apr 16;7:238. doi: 10.3389/fchem.2019.00238. eCollection 2019.

2.

Structure-Function Studies of Polymyxin B Lipononapeptides.

Gallardo-Godoy A, Hansford KA, Muldoon C, Becker B, Elliott AG, Huang JX, Pelingon R, Butler MS, Blaskovich MAT, Cooper MA.

Molecules. 2019 Feb 2;24(3). pii: E553. doi: 10.3390/molecules24030553.

3.

Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.

Jarrad AM, Ang CW, Debnath A, Hahn HJ, Woods K, Tan L, Sykes ML, Jones AJ, Pelingon R, Butler MS, Avery VM, West NP, Karoli T, Blaskovich MAT, Cooper MA.

J Med Chem. 2018 Dec 27;61(24):11349-11371. doi: 10.1021/acs.jmedchem.8b01578. Epub 2018 Dec 11.

4.

The Eagle Effect and Antibiotic-Induced Persistence: Two Sides of the Same Coin?

Prasetyoputri A, Jarrad AM, Cooper MA, Blaskovich MAT.

Trends Microbiol. 2019 Apr;27(4):339-354. doi: 10.1016/j.tim.2018.10.007. Epub 2018 Nov 15. Review.

PMID:
30448198
5.

Octapeptin C4 and polymyxin resistance occur via distinct pathways in an epidemic XDR Klebsiella pneumoniae ST258 isolate.

Pitt ME, Cao MD, Butler MS, Ramu S, Ganesamoorthy D, Blaskovich MAT, Coin LJM, Cooper MA.

J Antimicrob Chemother. 2019 Mar 1;74(3):582-593. doi: 10.1093/jac/dky458.

PMID:
30445429
6.

Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays.

Kavanagh A, Ramu S, Gong Y, Cooper MA, Blaskovich MAT.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01760-18. doi: 10.1128/AAC.01760-18. Print 2019 Jan.

7.

Antimicrobial Silver in Medicinal and Consumer Applications: A Patent Review of the Past Decade (2007⁻2017).

Sim W, Barnard RT, Blaskovich MAT, Ziora ZM.

Antibiotics (Basel). 2018 Oct 26;7(4). pii: E93. doi: 10.3390/antibiotics7040093. Review.

8.

Detection and Investigation of Eagle Effect Resistance to Vancomycin in Clostridium difficile With an ATP-Bioluminescence Assay.

Jarrad AM, Blaskovich MAT, Prasetyoputri A, Karoli T, Hansford KA, Cooper MA.

Front Microbiol. 2018 Jul 2;9:1420. doi: 10.3389/fmicb.2018.01420. eCollection 2018.

9.

Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?

Blaskovich MAT, Pitt ME, Elliott AG, Cooper MA.

Expert Rev Anti Infect Ther. 2018 Jun;16(6):485-499. doi: 10.1080/14787210.2018.1483240. Epub 2018 Jun 26. Review.

PMID:
29848132
10.

Silver bullets: A new lustre on an old antimicrobial agent.

Möhler JS, Sim W, Blaskovich MAT, Cooper MA, Ziora ZM.

Biotechnol Adv. 2018 Sep - Oct;36(5):1391-1411. doi: 10.1016/j.biotechadv.2018.05.004. Epub 2018 May 27. Review.

PMID:
29847770
11.

The Fight Against Antimicrobial Resistance Is Confounded by a Global Increase in Antibiotic Usage.

Blaskovich MAT.

ACS Infect Dis. 2018 Jun 8;4(6):868-870. doi: 10.1021/acsinfecdis.8b00109. Epub 2018 May 14.

PMID:
29757608
12.

Fluorescent Antibiotics: New Research Tools to Fight Antibiotic Resistance.

Stone MRL, Butler MS, Phetsang W, Cooper MA, Blaskovich MAT.

Trends Biotechnol. 2018 May;36(5):523-536. doi: 10.1016/j.tibtech.2018.01.004. Epub 2018 Feb 22. Review.

PMID:
29478675
13.

Multifactorial chromosomal variants regulate polymyxin resistance in extensively drug-resistant Klebsiella pneumoniae.

Pitt ME, Elliott AG, Cao MD, Ganesamoorthy D, Karaiskos I, Giamarellou H, Abboud CS, Blaskovich MAT, Cooper MA, Coin LJM.

Microb Genom. 2018 Mar;4(3). doi: 10.1099/mgen.0.000158. Epub 2018 Feb 12.

14.

Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria.

Velkov T, Gallardo-Godoy A, Swarbrick JD, Blaskovich MAT, Elliott AG, Han M, Thompson PE, Roberts KD, Huang JX, Becker B, Butler MS, Lash LH, Henriques ST, Nation RL, Sivanesan S, Sani MA, Separovic F, Mertens H, Bulach D, Seemann T, Owen J, Li J, Cooper MA.

Cell Chem Biol. 2018 Apr 19;25(4):380-391.e5. doi: 10.1016/j.chembiol.2018.01.005. Epub 2018 Feb 3.

15.

Developments in Glycopeptide Antibiotics.

Blaskovich MAT, Hansford KA, Butler MS, Jia Z, Mark AE, Cooper MA.

ACS Infect Dis. 2018 May 11;4(5):715-735. doi: 10.1021/acsinfecdis.7b00258. Epub 2018 Feb 19.

16.

Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria.

Blaskovich MAT, Hansford KA, Gong Y, Butler MS, Muldoon C, Huang JX, Ramu S, Silva AB, Cheng M, Kavanagh AM, Ziora Z, Premraj R, Lindahl F, Bradford TA, Lee JC, Karoli T, Pelingon R, Edwards DJ, Amado M, Elliott AG, Phetsang W, Daud NH, Deecke JE, Sidjabat HE, Ramaologa S, Zuegg J, Betley JR, Beevers APG, Smith RAG, Roberts JA, Paterson DL, Cooper MA.

Nat Commun. 2018 Jan 2;9(1):22. doi: 10.1038/s41467-017-02123-w.

17.

Structure-Activity and -Toxicity Relationships of the Antimicrobial Peptide Tachyplesin-1.

Edwards IA, Elliott AG, Kavanagh AM, Blaskovich MAT, Cooper MA.

ACS Infect Dis. 2017 Dec 8;3(12):917-926. doi: 10.1021/acsinfecdis.7b00123. Epub 2017 Oct 3.

PMID:
28960954
18.

Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes.

Han ML, Shen HH, Hansford KA, Schneider EK, Sivanesan S, Roberts KD, Thompson PE, Le Brun AP, Zhu Y, Sani MA, Separovic F, Blaskovich MAT, Baker MA, Moskowitz SM, Cooper MA, Li J, Velkov T.

ACS Infect Dis. 2017 Aug 11;3(8):606-619. doi: 10.1021/acsinfecdis.7b00065. Epub 2017 Jul 11.

19.

Institutional profile: Community for Open Antimicrobial Drug Discovery - crowdsourcing new antibiotics and antifungals.

Desselle MR, Neale R, Hansford KA, Zuegg J, Elliott AG, Cooper MA, Blaskovich MA.

Future Sci OA. 2017 Mar 24;3(2):FSO171. doi: 10.4155/fsoa-2016-0093. eCollection 2017 Jun.

20.

Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.

Ang CW, Jarrad AM, Cooper MA, Blaskovich MAT.

J Med Chem. 2017 Sep 28;60(18):7636-7657. doi: 10.1021/acs.jmedchem.7b00143. Epub 2017 May 22. Review.

PMID:
28463485
21.

Synthesis of octapeptin C4 and biological profiling against NDM-1 and polymyxin-resistant bacteria.

Becker B, Butler MS, Hansford KA, Gallardo-Godoy A, Elliott AG, Huang JX, Edwards DJ, Blaskovich MAT, Cooper MA.

Bioorg Med Chem Lett. 2017 Jun 1;27(11):2407-2409. doi: 10.1016/j.bmcl.2017.04.027. Epub 2017 Apr 12.

22.

Polishing the tarnished silver bullet: the quest for new antibiotics.

Blaskovich MA, Butler MS, Cooper MA.

Essays Biochem. 2017 Mar 3;61(1):103-114. doi: 10.1042/EBC20160077. Print 2017 Feb 28. Review.

23.

Enhancement of antibiotic-activity through complexation with metal ions - Combined ITC, NMR, enzymatic and biological studies.

Möhler JS, Kolmar T, Synnatschke K, Hergert M, Wilson LA, Ramu S, Elliott AG, Blaskovich MA, Sidjabat HE, Paterson DL, Schenk G, Cooper MA, Ziora ZM.

J Inorg Biochem. 2017 Feb;167:134-141. doi: 10.1016/j.jinorgbio.2016.11.028. Epub 2016 Nov 24.

PMID:
27984786
24.

Surface Ligand Density of Antibiotic-Nanoparticle Conjugates Enhances Target Avidity and Membrane Permeabilization of Vancomycin-Resistant Bacteria.

Hassan MM, Ranzoni A, Phetsang W, Blaskovich MA, Cooper MA.

Bioconjug Chem. 2017 Feb 15;28(2):353-361. doi: 10.1021/acs.bioconjchem.6b00494. Epub 2016 Dec 13.

PMID:
27959504
25.

Old dogs and new tricks in antimicrobial discovery.

Butler MS, Blaskovich MA, Owen JG, Cooper MA.

Curr Opin Microbiol. 2016 Oct;33:25-34. doi: 10.1016/j.mib.2016.05.011. Epub 2016 Jun 2. Review.

PMID:
27262526
26.

Fluorescent Trimethoprim Conjugate Probes To Assess Drug Accumulation in Wild Type and Mutant Escherichia coli.

Phetsang W, Pelingon R, Butler MS, Kc S, Pitt ME, Kaeslin G, Cooper MA, Blaskovich MA.

ACS Infect Dis. 2016 Oct 14;2(10):688-701. Epub 2016 Aug 16.

27.

Unusual Amino Acids in Medicinal Chemistry.

Blaskovich MA.

J Med Chem. 2016 Dec 22;59(24):10807-10836. doi: 10.1021/acs.jmedchem.6b00319. Epub 2016 Sep 30. Review.

PMID:
27589349
28.

Antibiotics in the clinical pipeline at the end of 2015.

Butler MS, Blaskovich MA, Cooper MA.

J Antibiot (Tokyo). 2017 Jan;70(1):3-24. doi: 10.1038/ja.2016.72. Epub 2016 Jun 29. Review.

PMID:
27353164
29.

Contribution of Amphipathicity and Hydrophobicity to the Antimicrobial Activity and Cytotoxicity of β-Hairpin Peptides.

Edwards IA, Elliott AG, Kavanagh AM, Zuegg J, Blaskovich MA, Cooper MA.

ACS Infect Dis. 2016 Jun 10;2(6):442-450. Epub 2016 Apr 29.

30.

Nitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis.

Jarrad AM, Debnath A, Miyamoto Y, Hansford KA, Pelingon R, Butler MS, Bains T, Karoli T, Blaskovich MA, Eckmann L, Cooper MA.

Eur J Med Chem. 2016 Sep 14;120:353-62. doi: 10.1016/j.ejmech.2016.04.064. Epub 2016 Apr 27.

31.

Chemical philanthropy: a path forward for antibiotic discovery?

Hansford KA, Blaskovich MA, Cooper MA.

Future Med Chem. 2016 Jun;8(9):925-9. doi: 10.4155/fmc-2016-0029. Epub 2016 May 26. No abstract available.

32.

Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling.

Croker DE, Monk PN, Halai R, Kaeslin G, Schofield Z, Wu MC, Clark RJ, Blaskovich MA, Morikis D, Floudas CA, Cooper MA, Woodruff TM.

Immunol Cell Biol. 2016 Sep;94(8):787-95. doi: 10.1038/icb.2016.43. Epub 2016 Apr 25.

33.

Short cationic lipopeptides as effective antibacterial agents: Design, physicochemical properties and biological evaluation.

Azmi F, Elliott AG, Marasini N, Ramu S, Ziora Z, Kavanagh AM, Blaskovich MA, Cooper MA, Skwarczynski M, Toth I.

Bioorg Med Chem. 2016 May 15;24(10):2235-41. doi: 10.1016/j.bmc.2016.03.053. Epub 2016 Mar 30.

PMID:
27048775
34.

Self-assembling lipopeptides with a potent activity against Gram-positive bacteria, including multidrug resistant strains.

Azmi F, Elliott AG, Khalil ZG, Hussein WM, Kavanagh A, Huang JX, Quezada M, Blaskovich MA, Capon RJ, Cooper MA, Skwarczynski M, Toth I.

Nanomedicine (Lond). 2015 Nov;10(22):3359-71.

PMID:
26909416
35.

Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B.

Gallardo-Godoy A, Muldoon C, Becker B, Elliott AG, Lash LH, Huang JX, Butler MS, Pelingon R, Kavanagh AM, Ramu S, Phetsang W, Blaskovich MA, Cooper MA.

J Med Chem. 2016 Feb 11;59(3):1068-77. doi: 10.1021/acs.jmedchem.5b01593. Epub 2016 Jan 27.

36.

Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity: comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells.

Huang JX, Kaeslin G, Ranall MV, Blaskovich MA, Becker B, Butler MS, Little MH, Lash LH, Cooper MA.

Pharmacol Res Perspect. 2015 Jun;3(3):e00148. doi: 10.1002/prp2.148. Epub 2015 May 15.

37.

Mucin Binding Reduces Colistin Antimicrobial Activity.

Huang JX, Blaskovich MA, Pelingon R, Ramu S, Kavanagh A, Elliott AG, Butler MS, Montgomery AB, Cooper MA.

Antimicrob Agents Chemother. 2015 Oct;59(10):5925-31. doi: 10.1128/AAC.00808-15. Epub 2015 Jul 13.

38.

Helping Chemists Discover New Antibiotics.

Blaskovich MA, Zuegg J, Elliott AG, Cooper MA.

ACS Infect Dis. 2015 Jul 10;1(7):285-7. doi: 10.1021/acsinfecdis.5b00044. Epub 2015 May 13.

PMID:
27622818
39.

Metronidazole-triazole conjugates: activity against Clostridium difficile and parasites.

Jarrad AM, Karoli T, Debnath A, Tay CY, Huang JX, Kaeslin G, Elliott AG, Miyamoto Y, Ramu S, Kavanagh AM, Zuegg J, Eckmann L, Blaskovich MA, Cooper MA.

Eur J Med Chem. 2015 Aug 28;101:96-102. doi: 10.1016/j.ejmech.2015.06.019. Epub 2015 Jun 18.

40.

Clostridium difficile drug pipeline: challenges in discovery and development of new agents.

Jarrad AM, Karoli T, Blaskovich MA, Lyras D, Cooper MA.

J Med Chem. 2015 Jul 9;58(13):5164-85. doi: 10.1021/jm5016846. Epub 2015 Mar 30. Review.

41.

A new antibiotic with potent activity targets MscL.

Iscla I, Wray R, Blount P, Larkins-Ford J, Conery AL, Ausubel FM, Ramu S, Kavanagh A, Huang JX, Blaskovich MA, Cooper MA, Obregon-Henao A, Orme I, Tjandra ES, Stroeher UH, Brown MH, Macardle C, van Holst N, Ling Tong C, Slattery AD, Gibson CT, Raston CL, Boulos RA.

J Antibiot (Tokyo). 2015 Jul;68(7):453-62. doi: 10.1038/ja.2015.4. Epub 2015 Feb 4.

42.

Cell- and biomarker-based assays for predicting nephrotoxicity.

Huang JX, Blaskovich MA, Cooper MA.

Expert Opin Drug Metab Toxicol. 2014 Dec;10(12):1621-35. doi: 10.1517/17425255.2014.967681. Epub 2014 Nov 10. Review.

PMID:
25382677
43.

Glycopeptide antibiotics: back to the future.

Butler MS, Hansford KA, Blaskovich MA, Halai R, Cooper MA.

J Antibiot (Tokyo). 2014 Sep;67(9):631-44. doi: 10.1038/ja.2014.111. Epub 2014 Aug 13. Review.

PMID:
25118105
44.

An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants.

Phetsang W, Blaskovich MA, Butler MS, Huang JX, Zuegg J, Mamidyala SK, Ramu S, Kavanagh AM, Cooper MA.

Bioorg Med Chem. 2014 Aug 15;22(16):4490-8. doi: 10.1016/j.bmc.2014.05.054. Epub 2014 Jun 14.

45.

Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours.

Zhang X, Blaskovich MA, Forinash KD, Sebti SM.

Br J Cancer. 2014 Aug 26;111(5):894-902. doi: 10.1038/bjc.2014.349. Epub 2014 Jul 1.

46.

Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin.

Cheng M, Ziora ZM, Hansford KA, Blaskovich MA, Butler MS, Cooper MA.

Org Biomol Chem. 2014 Apr 28;12(16):2568-75. doi: 10.1039/c3ob42428f.

47.

Lysophosphatidic acid acyltransferase beta regulates mTOR signaling.

Blaskovich MA, Yendluri V, Lawrence HR, Lawrence NJ, Sebti SM, Springett GM.

PLoS One. 2013 Oct 31;8(10):e78632. doi: 10.1371/journal.pone.0078632. eCollection 2013.

48.

Antibiotics in the clinical pipeline in 2013.

Butler MS, Blaskovich MA, Cooper MA.

J Antibiot (Tokyo). 2013 Oct;66(10):571-91. doi: 10.1038/ja.2013.86. Epub 2013 Sep 4. Review.

PMID:
24002361
49.

Antibacterial serrulatane diterpenes from the Australian native plant Eremophila microtheca.

Barnes EC, Kavanagh AM, Ramu S, Blaskovich MA, Cooper MA, Davis RA.

Phytochemistry. 2013 Sep;93:162-9. doi: 10.1016/j.phytochem.2013.02.021. Epub 2013 Apr 18.

PMID:
23602054
50.

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).

Gajewski TF, Salama AK, Niedzwiecki D, Johnson J, Linette G, Bucher C, Blaskovich MA, Sebti SM, Haluska F; Cancer and Leukemia Group B.

J Transl Med. 2012 Dec 10;10:246. doi: 10.1186/1479-5876-10-246.

Supplemental Content

Loading ...
Support Center